Drug intelligence / Profile preview

ARI-6000

Development stage: Preclinical
Lead developer: Arisaph Pharmaceuticals
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

ARI-6000 is an experimental fibroblast activation protein (FAP)–activated prodrug designed to remain largely inert in circulation and become pharmacologically active only within the tumor microenvironment, where FAP is overexpressed on cancer-associated fibroblasts. By exploiting proteolytic cleavage by FAP to release a cytotoxic payload locally, ARI-6000 aims to enhance antitumor efficacy while reducing systemic toxicity compared with conventional chemotherapy. It is being developed within Arisaph Pharmaceuticals’ tumor-activated prodrug oncology program as a targeted cancer therapeutic.

Targets

FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on ARI-6000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARI-6000.

Explore the full profile